Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stakes Claim With Phase I Study

0
590

Dallas, Texas 04/24/2014 (FINANCIALSTRENDS) –  Celldex Therapeutics, Inc. (NASDAQ:CLDX) was initiated by Bank of America for Phase I study of CDX-1401. This will treat solid tumors, which also includes follow-up of patients and news of this stock has been published in Science Translational Medicine.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been demonstrating technology for robust antibody and T-cell responses. There been evidence of benefits by patients for advanced cancer. The company proposes that by using the CDX-1401, will now prepare patients for better treatment for such advanced cancers by the use of CDX-1401. The drug will show better therapy for checkpoint inhibitors.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) holds a market capital of $1.31billion.The stock has a price range of$15.99and $14.59 along with 52week price range of $11.34 as well as $38.84. The shares of this stock opened at $15.93. EPSis-1.02. Outstanding shares for this stock are 89.63million.Beta is 2.41.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in recent times has stock institutional ownership of the range 88.50%, with the insider ownership in the range of 0.10%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in recent times has been in competition with PFE Inc., with GlaxoSmithKline as well as NorthWestBiothermal, along with BMY. The other participants include AgenusInc, besides Amgen Inc as well.

The company has been involved in the development of therapies which will offer relief from such medical conditions as cancer as well as a range of diseases which are in the range of difficult to treat diseases.

The drug candidate will now allow the company to offer a range of immunotherapeutic vaccine. Such vaccines are found to be of special use, targeting treatment of certain type is of cancer. The drug candidate will also include such as the drugs as CDX-110, CDX-011, CDX-1127 and CDX-110. These will also help in the treatment of epidermal growth of factor as well as receptor variant III.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.